View Older Stories View More Recent Stories
-
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
-
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
-
Form 3 Inhibrx, Inc. For: Aug 18 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
-
Novavax Reports Second Quarter 2020 Financial and Operational Results
-
Novavax Reports Second Quarter 2020 Financial and Operational Results
-
Saniona successfully raises USD 65 million (approximately SEK 567 million) in a directed issue of shares
-
Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy
-
T-knife Completes €66 Million Series A Financing to Develop Next-Generation T-Cell Therapies
-
T-knife Completes €66 Million Series A Financing to Develop Next-Generation T-Cell Therapies
-
Form SC 13D iTeos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimm
-
PMV Pharma Closes $70 Million in Series D Financing
-
Cerevel Therapeutics and SPAC Arya Sciences Acquisition Corp II (ARYBU) Announce Business Combination
-
Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development
-
Form 4 iTeos Therapeutics, Inc. For: Jul 28 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish
-
Form SC 13D Nkarta, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 3 Inozyme Pharma, Inc. For: Jul 23 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Olema Oncology Announces $54 Million Series B Financing
-
Verona Pharma plc (VRNA) Raises $200 Million in Oversubscribed Private Placement and Subscription
-
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
-
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
-
Form 3 Pandion Therapeutics, For: Jul 16 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Vaxart (VXRT) Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility (Earlier)
-
Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
-
Form SC 13G Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Verastem, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Closing of $135.7 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option To Purc
-
Form 3 Nkarta, Inc. For: Jul 09 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Therapeutics Acquisition Corp. (TXAC) Prices 11.8M Class A Share IPO at $10/Sh
-
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
-
Vor Biopharma Closes $110 Million Series B Financing
-
Bolt Biotherapeutics Closes $93.5 Million Series C Financing
-
Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
-
Form 3 Akouos, Inc. For: Jun 25 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Forma Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AAC
-
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AAC
-
Form 3 Forma Therapeutics Holdi For: Jun 18 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
-
Novavax (NVAX) Raises $200M from Private Placement with RA Capital
-
Novavax to Raise $200 Million from Private Placement with RA Capital
-
Novavax to Raise $200 Million from Private Placement with RA Capital
-
Form SC 13G/A TG THERAPEUTICS, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Everest Medicines Completes US$310 Million Series C Financing
-
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

